Inhibitor of Apoptosis Protein (IAP) Antagonists
US-2019135861-A1 · May 9, 2019 · US
Compounds useful in HIV therapy
US10870663B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10870663-B2 |
| Application number | US-202016897351-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 10, 2020 |
| Priority date | Nov 30, 2018 |
| Publication date | Dec 22, 2020 |
| Grant date | Dec 22, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having the structure: or a pharmaceutically acceptable salt thereof. 2. A salt according to claim 1 , wherein the salt is present as a hydrochloride salt. 3. The salt according to claim 2 , wherein the hydrochloride salt is a dihydrochloride salt. 4. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 5. The composition according to claim 4 , wherein said composition is adapted for parenteral administration. 6. A method of depleting latent HIV infected cells comprising administering to a subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof. 7. A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof. 8. A compound having the structure: 9. A pharmaceutical composition comprising a compound according to claim 8 , and a pharmaceutically acceptable excipient. 10. The composition according to claim 9 , wherein said composition is adapted for parenteral administration. 11. A method of depleting latent HIV infected cells comprising administering to a subject a compound of claim 8 . 12. A method of treating an HIV infection in a subject comprising administering to the subject a compound of claim 8 .
Assignees
Inventors
Classifications
- A61P31/18Primary
for HIV · CPC title
- C07D519/00Primary
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10870663B2 cover?
- The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.
- Who is the assignee on this patent?
- Glaxosmithkline Ip Dev Ltd, Univ North Carolina Chapel Hill, Viiv Healthcare Co
- What technology area does this patent fall under?
- Primary CPC classification A61P31/18. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).